[go: up one dir, main page]

FI870502A0 - Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja - Google Patents

Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja

Info

Publication number
FI870502A0
FI870502A0 FI870502A FI870502A FI870502A0 FI 870502 A0 FI870502 A0 FI 870502A0 FI 870502 A FI870502 A FI 870502A FI 870502 A FI870502 A FI 870502A FI 870502 A0 FI870502 A0 FI 870502A0
Authority
FI
Finland
Prior art keywords
producing
antibody
cell line
monoclonal antibodies
human monoclonal
Prior art date
Application number
FI870502A
Other languages
English (en)
Swedish (sv)
Other versions
FI94489C (fi
FI94489B (fi
FI870502L (fi
Inventor
Howard V Raff
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of FI870502A0 publication Critical patent/FI870502A0/fi
Publication of FI870502L publication Critical patent/FI870502L/fi
Application granted granted Critical
Publication of FI94489B publication Critical patent/FI94489B/fi
Publication of FI94489C publication Critical patent/FI94489C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI870502A 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja FI94489C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US82800586 1986-02-07
US94449586A 1986-12-19 1986-12-19
US94449586 1986-12-19

Publications (4)

Publication Number Publication Date
FI870502A0 true FI870502A0 (fi) 1987-02-06
FI870502L FI870502L (fi) 1987-08-08
FI94489B FI94489B (fi) 1995-06-15
FI94489C FI94489C (fi) 1995-09-25

Family

ID=27125154

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870502A FI94489C (fi) 1986-02-07 1987-02-06 Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja

Country Status (28)

Country Link
US (2) US5717071A (fi)
JP (1) JP2645343B2 (fi)
KR (1) KR870007697A (fi)
CN (1) CN87102167A (fi)
AT (1) AT398781B (fi)
BE (1) BE1000967A5 (fi)
CA (1) CA1339013C (fi)
CH (1) CH672072A5 (fi)
DE (1) DE3703711A1 (fi)
DK (1) DK63187A (fi)
ES (1) ES2009140A6 (fi)
FI (1) FI94489C (fi)
FR (1) FR2595946B1 (fi)
GB (1) GB2186592B (fi)
GR (1) GR870194B (fi)
HK (1) HK21795A (fi)
HU (1) HU203583B (fi)
IE (1) IE59627B1 (fi)
IL (1) IL81370A (fi)
IT (1) IT1207589B (fi)
LU (1) LU86761A1 (fi)
MX (1) MX9203629A (fi)
NL (1) NL8700286A (fi)
NO (1) NO176924C (fi)
NZ (2) NZ219187A (fi)
OA (1) OA08477A (fi)
PT (1) PT84258B (fi)
SE (1) SE468747B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256713A3 (en) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutic human antipseudomonas aeruginosa antibodies
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
DE3925161A1 (de) * 1989-03-15 1990-09-27 Boehringer Mannheim Gmbh Monoklonale, gegen eca gerichtete antikoerper und ihre verwendung
WO1990013660A2 (en) * 1989-05-09 1990-11-15 Cetus Corporation Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
PT635132E (pt) * 1992-03-19 2001-03-30 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
JPH08508240A (ja) * 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
JP5830460B2 (ja) * 2009-03-23 2015-12-09 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 癌および線維性疾患を治療する化合物、組成物、および方法
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
ES2981535T3 (es) * 2015-11-10 2024-10-09 Visterra Inc Conjugados de molécula de anticuerpo-fármaco que se unen específicamente al lipopolisacárido y usos de los mismos
ES2994374T3 (en) 2017-01-18 2025-01-23 Visterra Inc Antibody molecule-drug conjugates and uses thereof
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
AU567693B2 (en) * 1982-09-30 1987-12-03 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus

Also Published As

Publication number Publication date
MX9203629A (es) 1992-07-01
JP2645343B2 (ja) 1997-08-25
AT398781B (de) 1995-01-25
FI94489C (fi) 1995-09-25
HU203583B (en) 1991-08-28
FI94489B (fi) 1995-06-15
OA08477A (fr) 1988-07-29
BE1000967A5 (fr) 1989-05-30
DE3703711C2 (fi) 1993-06-24
SE8700467L (sv) 1987-08-08
PT84258B (pt) 1989-09-14
JPS62270535A (ja) 1987-11-24
CA1339013C (en) 1997-03-25
NZ233920A (en) 1990-12-21
HK21795A (en) 1995-02-24
DK63187A (da) 1987-08-08
GB2186592A (en) 1987-08-19
CH672072A5 (fi) 1989-10-31
US5837541A (en) 1998-11-17
FI870502L (fi) 1987-08-08
US5717071A (en) 1998-02-10
IE870320L (en) 1987-08-07
NL8700286A (nl) 1987-09-01
LU86761A1 (fr) 1987-09-15
GB2186592B (en) 1990-08-01
NZ219187A (en) 1990-12-21
SE8700467D0 (sv) 1987-02-06
NO176924C (no) 1995-06-21
CN87102167A (zh) 1988-02-03
IT1207589B (it) 1989-05-25
IT8719292A0 (it) 1987-02-06
DK63187D0 (da) 1987-02-06
IE59627B1 (en) 1994-03-09
GB8702689D0 (en) 1987-03-11
FR2595946A1 (fr) 1987-09-25
GR870194B (en) 1987-06-10
IL81370A0 (en) 1987-08-31
PT84258A (en) 1987-03-01
SE468747B (sv) 1993-03-15
NO176924B (no) 1995-03-13
IL81370A (en) 1991-06-30
FR2595946B1 (fr) 1991-10-04
KR870007697A (ko) 1987-09-21
ES2009140A6 (es) 1989-09-01
NO870476D0 (no) 1987-02-06
HUT46062A (en) 1988-09-28
NO870476L (no) 1987-08-10
DE3703711A1 (de) 1987-09-24
ATA26287A (de) 1994-06-15

Similar Documents

Publication Publication Date Title
FI870502A0 (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
FI873948L (fi) Menetelmä ihmisen kasvainkuoliotekijän (TNF) kanssa reagoivan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridisolulinja
IL76142A0 (en) Monoclonal antibody specific to human carcinoma tumorassociated antigen,hybrid cell lines producing the same and methods for the use thereof
FI954347L (fi) Monoklonaaliset vasta-ainekoostumukset ja monoklonaalisia vasta-aineita tuottavat hybridomat
FI20011804L (fi) Menetelmä ihmisen kantasolutekijän valmistamiseksi ja siihen soveltuva solu
FI925631A7 (fi) Monoklonaaliset vasta-aineet
HU896763D0 (en) Process for the preparation of bispecific monoclonal antibody
KR890700172A (ko) 금속-제2상 복합체 생산방법 및 그 생산물
IL88145A0 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
PT87688A (pt) Hybrid protein c and method for its preparation
NZ217339A (en) Immunoassay for progesterone using monoclonal antibodies
NO302176B1 (no) Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen
HUT43104A (en) Process for producing human antibodies
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
FI940811L (fi) Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat
ZA852426B (en) Monoclonal antibody specific for human basal cell surface antigen
ES546696A0 (es) Procedimiento de preparar anticuerpos monoclonales y metodo de preparar reactivos para detectar canceres
DE3689868D1 (de) Monoklonale Antikörper gegen menschliches Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und Verwendung.
EP0307476A4 (en) Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
FI862978L (fi) Onkofetaalisia spesifisiä monoklonaalisia vasta-aineita, menetelmä niiden valmistamiseksi ja niiden käyttö.
FI902735A7 (fi) Monoklonaalinen vasta-aine, joka reagoi tiettyyn laajasti erilaisissa ihmisleukemia- ja lymfomasoluissa esiintyvään antigeeniin ja menetelmä sen käyttämiseksi diagnoosiin ja hoitoon
FR2606421B1 (fr) Anticorps monoclonaux antigram (-) procede de preparation et applications
EP0185391A3 (en) Method for the purification of the hbc antigen and method for the measurement of hbc antibodies by using said purified hbc antigen
EP0267601A3 (en) Anti-pci monoclonal antibody
EP0157574A3 (en) Antitetanic antibody producing human-human hybridoma and method of producing the same

Legal Events

Date Code Title Description
FG Patent granted

Owner name: BRISTOL-MYERS SQUIBB COMPANY

BB Publication of examined application
GB Transfer or assigment of application

Owner name: BRISTOL-MYERS SQUIBB COMPANY

FD Application lapsed
MM Patent lapsed

Owner name: BRISTOL-MYERS SQUIBB COMPANY